Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Scivita Medical Technology / Equity Capital Markets

<ul>
<li>Scivita is a China-based medical device company with a focus on single-use endoscope. The company is looking to raise up to USD100 m via a Hong Kong listing.</li>
<li>In this note, we look at the company's background, the industry dynamics and the company's products.</li>
<li>We think the company has a decent investor backing and management team but the intense competition is the main issue.</li>
</ul>


Scivita is a China-based medical device company with a focus on single-use endoscope. The company is looking to raise up to USD100 m via a Hong Kong listing.
In this note, we look at the company's background, the industry dynamics and the company's products.
We think the company has a decent investor backing and management team but the intense competition is the main issue.


Scivita (新光维医疗) Pre-IPO: Intense Competition Ahead